ESC 365 - Novel oral pathways in LDL-c lowering therapy: the new promise of oral CETP inhibitors

Open Access

Novel oral pathways in LDL-c lowering therapy: the new promise of oral CETP inhibitors

Session: The LDL-c challenge in patients with high cardiovascular risk: integrating innovative therapies in clinical management

Topic: Lipid-Lowering Agents

Speaker: Professor E. Michos (Baltimore, US)

Sponsored by PACE-CME – Supported by an unrestricted educational grant from Amgen, Sanofi, NewAmsterdam Pharma and Viatris

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Erin Michos

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

6 presentations

3 followers

5 more presentations in this session

Introduction

Speaker: Professor J. Kastelein (Amsterdam, NL)

The evolving need and challenges to reach LDL-c targets in high-risk patients

Speaker: Professor K. Ray (London, GB)

Oral LDL-c lowering therapies - the basis of prevention

Speaker: Professor L. Tokgozoglu (Ankara, TR)

PCSK9i: expanding benefits across the spectrum of cardiovascular disease

Speaker: Professor F. Martens (Amsterdam, NL)

Discussion

Speaker: Professor K. Ray (London, GB) Professor J. Kastelein (Amsterdam, NL) Professor F. Martens (Amsterdam, NL) Professor E. Michos (Baltimore, US)

Access the full session

The LDL-c challenge in patients with high cardiovascular risk: integrating innovative therapies in clinical management

Speakers: Professor E. Michos, Professor J. Kastelein, Professor K. Ray, Professor L. Tokgozoglu, Professor F. Martens...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources